TransPerfect Expands Life Sciences Capabilities with Synterex Acquisition

  • TransPerfect acquired Synterex, a clinical and regulatory writing firm, on October 1, 2026.
  • Synterex specializes in AI-assisted authoring and content management for biotech and pharmaceutical industries.
  • The acquisition integrates Synterex’s AgileWriter.ai® software with TransPerfect’s existing medical writing capabilities.
  • Synterex will operate as a division of TransPerfect Life Sciences, with its leadership remaining in place.

TransPerfect’s acquisition of Synterex underscores the growing trend of AI integration in life sciences, particularly in streamlining regulatory and clinical documentation. The deal positions TransPerfect to offer end-to-end solutions, from content creation to submission, addressing inefficiencies in a highly regulated industry. The strategic move aligns with broader industry shifts toward automation and AI-driven efficiencies in drug development and commercialization.

Integration Challenges
How TransPerfect will merge Synterex’s AI-enabled solutions with its existing workflows without disrupting client operations.
Market Positioning
Whether the acquisition strengthens TransPerfect’s competitive edge in the life sciences sector.
Regulatory Adaptation
The pace at which AI-assisted medical writing tools gain broader acceptance in highly regulated environments.